Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Nektar's New Old Drug

Motley Fool Inside Value pick Pfizer (NYSE: PFE  ) closed the chapter on its inhalable insulin experiment with Nektar Therapeutics (Nasdaq: NKTR  ) today. In exchange for giving Nektar $135 million in cash, Pfizer no longer has to market Exubera.

Pfizer's marketing of Exubera has been a total disaster since its approval in January 2005. Insurers were unwilling to pay for the drug, and national health-care authorities, for example in the U.K., limited its use to only a small subset of diabetes patients. Sales of the drug were only $12 million in the first nine months of 2007.

But despite all this, there is still value with Exubera. While MannKind (Nasdaq: MNKD  ) , Eli Lilly (NYSE: LLY  ) and Novo Nordisk (NYSE: NVO  ) all have potentially better inhalable insulins in late-stage development, Exubera could still be a complementary backup compound for one of the established diabetes leaders like Merck (NYSE: MRK  ) or Sanofi-Aventis (NYSE: SNY  ) .

Sanofi in particular may have an interest in reacquiring the rights to Exubera, as it has intimate knowledge of the drug after having been a partner on the compound before Pfizer bought out its stake.

With the smaller and easier to use inhaler that Nektar is testing in phase 1 trials, the right partner could probably eventually turn Exubera into a $100 million to $200 million a year compound. This is far from the $2 billion a year Pfizer was predicting, but would at least provide some royalty and manufacturing revenue to Nektar.

The $135 million that Nektar received from Pfizer, combined with its expected year-end cash balance of approximately $365 million, will be useful in paying down the $315 million in debt Nektar has coming due in 2012.

Any upfront payments from a potential Exubera marketing partner will likely be modest (if any), so Nektar needs all the cash it can get, now that raising capital has become much more expensive with its share price so low and profitability so far away.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 540158, ~/Articles/ArticleHandler.aspx, 10/23/2016 4:20:27 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
NKTR $13.34 Down -0.41 -2.98%
Nektar Therapeutic… CAPS Rating: ***
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***
MNKD $0.59 Down -0.02 -2.53%
MannKind CAPS Rating: *
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
NVO $41.50 Up +0.46 +1.12%
Novo Nordisk CAPS Rating: *****
SNY $37.75 Down -0.32 -0.84%
Sanofi CAPS Rating: *****